in vitro News and Research

RSS

Data from Cempra's CEM-101 Phase 2 trial on N. gonorrhoeae infections to be presented at ECCMID

Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrating that CEM-101 (solithromycin) is active against antibiotic-resistant strains of N. gonorrhoeae.

31 Mar 2012

TRIM28 protein essential after fertilisation to preserve epigenetic marks on imprinted genes

An international team led by scientists at A*STAR's Institute of Medical Biology (IMB) discovered that a protein, called TRIM28, normally present in the mother's egg, is essential right after fertilisation, to preserve certain chemical modifications or 'epigenetic marks' on a specific set of genes.

30 Mar 2012

Ember adds Joslin's BMP7 technology to brown fat intellectual property portfolio

Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the completion of an agreement with the Joslin Diabetes Center to exclusively license intellectual property covering bone morphogenetic protein 7 (BMP7), which has been shown to play a role in the regulation of brown fat development.

29 Mar 2012

New technique could restore fertility of boys undergoing cancer treatment

Treatments for childhood cancers are increasingly successful with cure rates approaching 80%, but success often comes with a downside for the surviving men: the cancer treatments they received as boys can leave them sterile as adults. Now, a research team led by Ralph Brinster of the University of Pennsylvania School of Veterinary Medicine has completed a 14-year experiment that gives hope for a technique that could restore their fertility.

29 Mar 2012

New treatment approach halts spread of cancer cells into normal brain tissue

Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.

29 Mar 2012

Researchers design new treatment approach for invasive brain tumors

Researchers from Emory and the Georgia Institute of Technology have designed a new treatment approach that appears to halt the spread of cancer cells into normal brain tissue in animal models.

29 Mar 2012

FDA clears BD MAX assay for detecting GBS DNA in Lim Broth cultures

BD announced today the U.S. Food and Drug Administration clearance of the BD MAX Group B Streptococcus (GBS) Assay and Clinical Laboratory Improvement Amendments (CLIA) moderate complexity test categorization on the second-generation BD MAX System.

From BD (Becton, Dickinson and Company) 29 Mar 2012

EU's Safety Evaluation Ultimately Replacing Animal Testing initiative tests Roche's xCELLigence system

Roche's xCELLigence RTCA System is being used in the European Union's SEURAT (Safety Evaluation Ultimately Replacing Animal Testing) initiative to run five years from 2011 to 2016.

From Roche Sequencing and Life Science 29 Mar 2012

EU-funded project to help control appetite, combat obesity

The University of Liverpool is leading a £6milllion European project to develop and test new food products with satiating qualities to help control appetite, manage weight and combat obesity.

29 Mar 2012

Pulsed photoacoustic techniques can diagnose different cancer cell types

Researchers have developed multiple techniques and procedures to detect cancer cells during the earliest stages of the disease or after treatment. But one of the major limitations of these technologies is their inability to detect the presence of only a few cancer cells.

28 Mar 2012

Researchers develop gut-on-a-chip microdevice

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have created a gut-on-a-chip microdevice lined by living human cells that mimics the structure, physiology, and mechanics of the human intestine-even supporting the growth of living microbes within its luminal space.

28 Mar 2012

Gold nanoparticles used to introduce chemical residues into the immune system

Developing a drug or vaccine requires a delicate balancing act with the immune system. On one hand, medications need to escape detection by the immune system in order to perform their function. But vaccinations - de-activated versions of a disease or virus - need to do the reverse. They prompt the immune system to create protective antibodies.

27 Mar 2012

UI receives three grants to hasten discovery of new TB therapeutics

Forty-five years. That's how long it's been since the last drug - rifampin - hit the market to treat tuberculosis, an infection that affects nearly one third of the world's population and causes 1.8 million deaths annually. The University of Illinois at Chicago College of Pharmacy has received three new federally-funded grants to hasten the discovery of new therapeutic treatments.

23 Mar 2012

New medical education portal - Lipoprotein Perspectives - launched

LipoScience, Inc., an in vitro diagnostic company advancing patient care by developing high value proprietary clinical tests using nuclear magnetic resonance (NMR) technology, announced the launch of Lipoprotein Perspectives - a medical education portal featuring experts in clinical and preventive cardiology, endocrinology, and lipidology - at www.lipoprotein.org.

19 Mar 2012

Ampio completes partial planned interim review in Optina trial for diabetic macular edema

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane completed two phase III studies, Ampion-completed proof of concept studies and Optina), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina trial for diabetic macular edema.

19 Mar 2012

New book on reproductive treatments

In Vitro Fertilization [IVF] and the related technologies of assisted reproduction are no longer experimental procedures. In some European countries as many as 4% of all babies born are conceived by IVF, and in every kindergarten classroom there will no doubt be at least one IVF child. Assisted reproduction is the solution to today's epidemic of infertility.

17 Mar 2012

Fertility preservation for delaying childbearing may prove too costly for society

Freezing eggs or ovarian tissue for the sole purpose of delaying childbearing for social reasons may prove too costly for society, according to a recent analysis by a University of Illinois at Chicago researcher.

15 Mar 2012

Even low-dose nanoparticles could have big impact on long-term health

Nanoparticles are everywhere. From cosmetics and clothes, to soda and snacks. But as versatile as they are, nanoparticles also have a downside, say researchers at Binghamton University and Cornell University in a recent paper published in the journal Nature Nanotechnology. These tiny particles, even in low doses, could have a big impact on our long-term health.

9 Mar 2012

New hybrid aspirin shrinks tumors, curbs cancer cell growth

The humble aspirin may soon have a new role. Scientists from The City College of New York have developed a new aspirin compound that has great promise to be, not only an extremely potent cancer-fighter, but even safer than the classic medicine cabinet staple.

9 Mar 2012

Enzo Biochem to unveil data on AmpiProbe HCV assay at ESCMID meeting

Enzo Biochem Inc. announced today that the company will present for the first time peer-reviewed data on detection of hepatitis C virus (HCV) using its novel AmpiProbe technology platform, which provides low cost and high sensitivity real-time nucleic acid amplification assays.

9 Mar 2012